Pollakiuria and Flomax


Pollakiuria Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for pollakiuria

pollakiuria treatment research studies

Flomax clinical trials, surveys and public health registries

Find Drug Side Effect reports

Flomax Side Effects

Dizziness (303)
Iris Disorder (202)
Nocturia (196)
Procedural Complication (144)
Pollakiuria (139)
Dysuria (134)
Fatigue (124)
Miosis (122)
Vision Blurred (113)
Rhinorrhoea (110)
Insomnia (106)
Hypotension (102)
Syncope (100)
Dyspnoea (98)
Headache (97)
Loss Of Consciousness (97)
Ejaculation Failure (96)
Cataract (95)
Cataract Operation Complication (93)
Back Pain (89)
Iridocele (51)
Fall (49)
Erectile Dysfunction (49)
Rash (48)
Semen Volume Decreased (48)
Floppy Iris Syndrome (46)
Nasal Congestion (45)
Pruritus (44)
Nausea (44)
Pain (43)
Blood Pressure Decreased (42)
Somnolence (41)
Prostate Cancer (40)
Asthenia (40)
Diarrhoea (39)
Constipation (38)
Middle Insomnia (37)
Retrograde Ejaculation (36)
Urine Flow Decreased (36)
Urinary Incontinence (36)
Urinary Retention (34)
Pupillary Disorder (30)
Chest Pain (27)
Dry Mouth (27)
Urinary Tract Infection (27)
Visual Acuity Reduced (25)
Palpitations (25)
Pain In Extremity (25)
Cerebrovascular Accident (24)
Cough (24)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Pollakiuria Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Gabapentin in Treating Overactive Bladder
Conditions: Urinary Frequency;   Urinary Urgency;   Nocturia;   Incontinence;   Detrusor Uninhibited Activity;   Quality of Life
Interventions: Drug: Gabapentin;   Drug: Solifenacin Succinate;   Drug: Placebo drugs
Outcome Measures: improvement of symptom domain means decreased frequency to less than 8 micturitions per 24 hours, no urgency noted per 24 hrs and less that 3 wakening at bedtime for micturation.;   Improvement of bladder function domain means increased bladder capacity and decreased overactive detrusor as recorded in urodynamic study.;   Improvement in quality of life domain means increased overall quality of life as perceived and result in OAB-q
2 Recruiting Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Condition: Urinary Incontinence, Urge
Interventions: Drug: Anticholinergic medications;   Behavioral: Hypnotherapy
Outcome Measures: Urgency Urinary Incontinence episodes recorded on voiding diaries;   Evoked brain activation and resting connectivity on functional MRI;   Urinary urge incontinence cure;   Questionnaire scores;   urinary frequency and pad counts;   Irritable bowel syndrome and bowel symptoms and/or Painful Bladder/Interstitial Cystitis in this population
3 Unknown  Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)
Conditions: Urinary Frequency;   Urinary Urgency;   Nocturia
Intervention: Drug: Solifenacin PO
Outcome Measures: Change in number of micturitions per 24 hours utilizing a 3 day micturition diary;   Change in mean nocturia episodes/24 hours based on 3 day diary
4 Recruiting Development of Novel Cystometrics for Overactive Bladder
Condition: Urinary Frequency/Urgency
Outcome Measure: Overactive Bladder/Urgency
5 Unknown  A Targeted Falls Prevention Program in Rehabilitation In-Patients
Condition: Accidental Falls
Intervention: Other: Multidisciplinary falls prevention
Outcome Measure: Rate of falls and fall-related injury
6 Unknown  A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
Conditions: Stress Urinary Incontinence;   Urgency Urinary Incontinence
Intervention: Drug: solifenacin
Outcome Measures: Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12;   Percent change in the mean number of urge urinary incontinence episodes per 24 hours;   Change in the mean number of urge urinary incontinence episodes per 24 hours;   Change in the mean frequency of urination per 24 hours;   Percent change in the mean frequency of urination;   Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours;   Change in the mean number of severe urgency episodes per 24 hours;   Changes in overactive bladder symptom score (OABSS) questionnaire;   Changes in short urogenital distress inventory (UDI-6);   Changes in short incontinence impact questionnaire (IIQ-7);   Safety assessed by the incidence and severity of side effects
7 Recruiting Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome
Condition: Overactive Bladder Syndrome
Interventions: Device: TENS 1-1;   Device: TENS 1-2;   Device: TENS 2-2;   Device: TENS 0-1
Outcome Measures: Change in urinary frequence in 12 sessions.;   Change in Nocturia in 12 sessions.;   Change in urinary urgence in 12 sessions.;   Change in urinary urge-incontinence in 12 sessions.
8 Recruiting Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Conditions: Overactive Bladder;   Lower Urinary Tract Symptoms
Interventions: Behavioral: Behavioral training;   Drug: Tolterodine + tamsulosin
Outcome Measures: Change in frequency of urination;   Urgency;   Urinary incontinence;   Nocturia;   Patient satisfaction;   Patient perceptions of improvement;   Overactive Bladder Questionnaire (OAB-q);   International Prostate Symptom Score (IPSS)
9 Not yet recruiting Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms
Condition: Overactive Bladder
Intervention: Device: Sports TENS 2
Outcome Measures: Change in day and night-time frequency of micturitions;   Change in a number of urgency and urge incontinence episodes;   Change in quality of life in patients with overactive bladder syndrome at the end of TENS treatment
10 Unknown  Premarin Versus Toviaz for Treatment of Overactive Bladder
Condition: Overactive Bladder
Intervention: Drug: Toviaz, Premarin Vaginal Cream
Outcome Measures: Urinary frequency as measured by a 3 day voiding diary;   Lifestyle Impact of Overactive Bladder as measured using 3 validated questionnaires: OAB-Q, PPBC, and Urgency Severity and Impact Questionnaire
11 Unknown  Genetic Studies in Interstitial Cystitis
Conditions: Interstitial Cystitis;   Painful Bladder Syndrome;   Chronic Pelvic Pain Syndrome
Outcome Measure:
12 Recruiting Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
Condition: Transplantation Infection
Interventions: Drug: Cidofovir;   Other: No Cidofovir
Outcome Measure: Number of Patients with Microbiologic Response
13 Unknown  Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Condition: Overactive Bladder in Parkinson's Disease
Interventions: Drug: solifenacin succinate (VESIcare);   Drug: placebo
Outcome Measures: The primary objective of this study is to measure the efficacy of solifenacin succinate (VESIcare) in reducing the mean number of micturitions per 24 hour period in Parkinson's disease (PD) patients as measured by voiding diaries.;   To examine the effect of solifenacin succinate (VESIcare) on urinary incontinence severity;   To examine the effect of solifenacin succinate (VESIcare) on Parkinson's disease severity;   To examine the effect of solifenacin succinate (VESIcare) on quality of life
14 Recruiting Therapy of the Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: solifenacin;   Procedure: PFMT and WBVT
Outcome Measures: Change of patient perception of bladder condition (PPBC);   Change in micturitions/24h based on a 3-day micturition diary;   Change of urgency episodes (grade ≥3) /24h;   Change in volume voided per micturition;   Change in number of incontinence and urge incontinence episodes/24h;   Change in number of pads used/24h
15 Recruiting The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia
Condition: Nocturia
Intervention: Behavioral: SyBeMeP (Systemized Behavioural Modification education Program)
Outcome Measures: Decrease in urinary frequency (No. of nocturia);   Voiding diary indices;   IPSS;   ICIQ-nocturia;   patient's perception of bladder condition (PPTB);   patient's satisfaction on the education
16 Unknown  Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Condition: Overactive Bladder
Intervention: Drug: Botox/Placebo
Outcome Measure: The primary efficacy Parameter is frequency of micturition (3-day voiding diary)
17 Recruiting Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine
Condition: Recurrent Urinary Tract Infection
Interventions: Drug: LVX-AMX;   Drug: TCM
Outcome Measures: Recovery of recurrent urinary tract infection;   Urinary albumin;   WBC conversion;   Urination frequency;   Recurrence;   urgency
18 Recruiting Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment
Condition: Interstitial Cystitis
Interventions: Drug: Botulinum toxin A;   Drug: Normal saline instillation
Outcome Measures: Net change of Patient Perception of Visual Analogue Scale (VAS);   Net change of Patient Perception of global response assessment (GRA);   Net change of O'Leary-Sant symptom and problem indexes;   Net change of the functional bladder capacity (FBC);   Net change of the number of urinary frequency;   Net change of the number of nocturnal;   Net change of the Quality of Life (QoL);   Net change of the maximal flow rate (Qmax);   Net change of the voided volume;   Net change of the residual urine volume (PVR)
19 Not yet recruiting A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Condition: Overactive Bladder (OAB)
Interventions: Drug: Myrbetriq;   Drug: Detrol LA
Outcome Measures: Patient tolerability assessed by the Tolerability Scale of the Overactive Bladder-satisfaction (OAB-S) questionnaire;   Patient preference from a 5-point scale;   Scales of the OAB-S questionnaire;   Change from baseline in number of incontinence episodes per 24 hours;   Change from baseline in number of micturitions per 24 hours
20 Recruiting Bladder Thermal Distention for Patients With Refractory Overactive Bladder
Condition: Overactive Bladder
Intervention: Procedure: Bladder Thermal Distention
Outcome Measures: Urgency Questionnaire;   Daily frequency of micturitions on Bladder Diary